Compare Moderna, Inc. (MRNA) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? Moderna, Inc. trades at $63.69 (market cap $24.18B), while Virgin Galactic Holdings, Inc. trades at $2.9 (market cap $498.02M). The key difference: Moderna, Inc. is far larger — about 48.6× Virgin Galactic Holdings, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | SPCE | |
|---|---|---|
Market Cap | $24.18B | $498.02M |
Sector | Health | Industrials |
52-Week High | $81.80 | $7.52 |
52-Week Low | $22.36 | $2.17 |
Enterprise Value | $20.33B | $597.87M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Virgin Galactic (SPCE) trades at $3.26, up 0.77% today, with technical indicators showing bullish momentum despite overbought RSI readings. The company continues to face significant fundamental challenges with negative profit margins (-19,781.3% net income margin) and declining revenue, though recent earnings have consistently beaten expectations. Cash flow remains negative but shows improvement trend from -$207M in 2022 to -$35M in 2025.
While technical momentum appears positive, SPCE's fundamental weakness and high cash burn present substantial risks. The stock offers speculative appeal for investors betting on space tourism commercialization, but requires careful risk management given persistent losses and competitive pressures in the emerging space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
